RNF214 silencing attenuates prostate cancer progression and modulates mTOR signaling through CAV1 ubiquitination
Zongqiang Wu, Zhiming Huang, Shangfan Liao · 2026
Read RNF214 silencing attenuates prostate cancer progression and modulates mTOR signaling through CAV1 ubiquitination by Zongqiang Wu, Zhiming Huang, Shangfan Liao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13479834.txt.
Description
Wu and co-authors studied a protein tagging enzyme called RNF214 in prostate cancer in 2026, finding it marks another protein, CAV1, for destruction and thereby keeps a growth circuit running. In patient tissue, RNF214 ran high while CAV1 ran low, an inverse pairing seen in both gene activity and protein levels. The team silenced each gene in cancer cells and in mouse tumor grafts to test the chain of cause and effect.
Silencing RNF214 slowed cancer cell growth and migration and let CAV1 levels recover in the treated cell lines. The two proteins bind directly, and RNF214 attaches the disposal tag that sends CAV1 to be broken down, confirming the mechanism in pull-down tests. Silencing both genes together restored growth and revived the mTOR growth pathway, and mouse grafts showed the same reversal, marking the pair as a drug target candidate.
Catalog record
| CREATOR | Zongqiang Wu, Zhiming Huang, Shangfan Liao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |